Aquatic Capital Management’s Travere Therapeutics TVTX Stock Holding History

Aquatic Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.05M	Sell	35,392 -23,727	-40%	-$709K	0.03%	548
2025 Q4	$2.26M	Buy	+59,119	New	+$1.92M	0.06%	355
2025 Q2	–	Sell	-64,762	Closed	-$1.16M	–	1553
2025 Q1	$1.16M	Buy	64,762 +32,795	+103%	+$666K	0.03%	564
2024 Q4	$557K	Buy	+31,967	New	+$565K	0.02%	690
2024 Q3	–	Sell	-3,100	Closed	-$25.5K	–	1557
2024 Q2	$25.5K	Buy	+3,100	New	+$20.9K	﹤0.01%	1080
2023 Q3	–	Sell	-2,600	Closed	-$40K	–	1672
2023 Q2	$40K	Sell	2,600 -2,900	-53%	-$52.8K	﹤0.01%	1034
2023 Q1	$124K	Buy	+5,500	New	+$117K	0.01%	701

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aquatic Capital Management's TVTX Position: Q1 2026 in Review

Aquatic Capital Management reduced its Travere Therapeutics (TVTX) stake by 40% in Q1 2026, selling an estimated $709K and leaving 35,392 shares worth $1.05M. The position accounts for 0.03% of the portfolio, ranked #548.

Aquatic Capital Management first reported a position in TVTX in Q1 2023 and has held it in 7 quarters since. The position peaked at $2.26M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Aquatic Capital Management held 35,392 shares of Travere Therapeutics worth $1.05M as of Q1 2026.
Aquatic Capital Management sold 23,727 Travere Therapeutics shares in Q1 2026, an estimated $709K.
Travere Therapeutics made up 0.03% of Aquatic Capital Management's portfolio in Q1 2026, its #548 holding.
Aquatic Capital Management first reported a position in Travere Therapeutics in Q1 2023 and has held it in 7 quarters since.
Aquatic Capital Management's Travere Therapeutics position peaked at $2.26M in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.